There has been a surge of over 5,000 people seeking polylaminin from Cristália and the courts, raising concerns among neurosurgeons about the substance's safety due to unverified efficacy.
In recent weeks, more than 5,000 individuals have approached Cristália's customer service and the Brazilian judicial system in an effort to access polylaminin before the completion of clinical trials. This alarming trend has drawn the attention of neurosurgeons, who are voicing concerns regarding the potential risks associated with utilizing a substance whose safety and effectiveness have not yet been established. As inquiries escalate, the implications for patient safety and public health grow increasingly serious.
As of the last Friday, a total of 5,400 requests has been made to Cristália's customer service department, which is the sponsor of the clinical trials and the manufacturer of polylaminin. The Brazilian health regulatory agency, Anvisa, has received 59 court orders requesting the use of this substance outside the approved clinical settings. Although the agency has granted an allowance for 33 patients to partake in a compassionate use program, which permits treatment outside clinical trials, these exceptions underscore the urgent need for rigorous clinical evaluation before wider application.
The clinical study currently allowed is a phase 1 trial focusing on the safety evaluation of polylaminin in five patients with acute spinal cord injuries, emphasizing the importance of administering treatment within 72 hours post-trauma. The rush for polylaminin amidst ongoing uncertainties about its safety profile raises a critical question: how should regulatory bodies balance the demand for immediate access to potentially life-saving treatments against the necessity for thorough scientific validation? This situation reflects broader challenges within medical ethics and public health policy when addressing unproven therapies in dire circumstances.
